Rigel Pharmaceuticals (RIGL)

$44.64 +0.70 (1.59%)
Market Cap 810.26M
Revenue (ttm) 179.28M
Net Income (ttm) 17.49M
EPS (ttm) N/A
PE Ratio 7.12
Forward PE 6.72
Profit Margin 9.76%
Debt to Equity Ratio 0.25
Volume 101,800
Avg Vol 588,126
Day's Range N/A - N/A
Shares Out 18.15M
Stochastic %K 95%
Beta 1.11
Analysts Sell
Price Target $51.20

Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a suscept...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 1100
Fax: 650 624 1101
Address:
611 Gateway Boulevard, Suite 900, South San Francisco, United States
SmartOptionsAlert
SmartOptionsAlert Dec. 25 at 10:43 PM
🔎 $RIGL Options Scan Update (16:43 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 25 at 4:57 PM
Enter: $RIGL Calls Strike Price: $45 Expiry Date: JAN 16 2026 Buy in Price: $2.00 - $4.60 Sell Price: $3.04 Profit : +52% (Turn every $1 into $1.52) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
1iquid
1iquid Dec. 25 at 10:09 AM
💎 Liquid® Live Actionable Trade Asset: $RIGL Contracts: $RIGL June 18, 2026 $45 Calls Scale in: $7.07- $8.64 Scale out: $27.49-$47.13 Profit Potential : 211% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
B4I4QQTRU18
B4I4QQTRU18 Dec. 25 at 12:27 AM
$RIGL 2,824,418 shares short. Not as much as I thought based on the two heavy down days. But still a lot to cover. ~16%. Board please announce a buy back plan or a drug addition. Sitting on cash is not a good look.
1 · Reply
Berakhot
Berakhot Dec. 24 at 3:38 PM
$RIGL indeed... business channel's off... trading done, fireplace stoked, rush is over, a few gifts to wrap. Christmas eve is here and delicious food ready for tomorrow. Wish you and yours a Merry Christmas Rigelians and a Happy New Years to come. https://www.youtube.com/watch?v=jBjt5gFbNYI
0 · Reply
GO_DAWGS
GO_DAWGS Dec. 24 at 1:14 PM
$RIGL Merry Christmas all!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 7:05 AM
Enter: $RIGL Calls Strike Price: $45 Expiry Date: JAN 16 2026 Buy in Price: $1.60 - $1.68 Sell Price: $3.52 Profit : +120% (Turn every $1 into $2.20) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
B4I4QQTRU18
B4I4QQTRU18 Dec. 23 at 8:31 PM
$RIGL Tomorrow new short interest report. About Two weeks, business update. IMO, blow out 4Q. Enjoy your holidays.
0 · Reply
MaxKlim
MaxKlim Dec. 23 at 3:57 PM
$RIGL https://www.marketbeat.com/instant-alerts/rigel-pharmaceuticals-nasdaqrigl-upgraded-to-buy-at-wall-street-zen-2025-12-21/
0 · Reply
GO_DAWGS
GO_DAWGS Dec. 23 at 2:59 PM
$RIGL be ready when they try to drag it down … dry powder!!!
0 · Reply
Latest News on RIGL
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Dec 7, 2025, 9:30 AM EST - 18 days ago

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Rigel Pharma: Q3 Earnings Showcase Robust Growth

Nov 26, 2025, 8:15 AM EST - 4 weeks ago

Rigel Pharma: Q3 Earnings Showcase Robust Growth

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 8:05 AM EST - 4 weeks ago

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

Nov 17, 2025, 8:05 AM EST - 5 weeks ago

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

Rigel to Present at the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 8:05 AM EST - 6 weeks ago

Rigel to Present at the Jefferies Global Healthcare Conference in London

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:06 PM EST - 7 weeks ago

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:01 PM EST - 7 weeks ago

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

Nov 3, 2025, 9:05 AM EST - 7 weeks ago

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Oct 30, 2025, 2:20 PM EDT - 2 months ago

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

Oct 29, 2025, 8:05 AM EDT - 2 months ago

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS

Oct 8, 2025, 8:05 AM EDT - 2 months ago

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Oct 3, 2025, 8:05 AM EDT - 2 months ago

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion

Sep 25, 2025, 10:53 PM EDT - 3 months ago

Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion

Rigel to Participate in Upcoming September Investor Conferences

Aug 26, 2025, 8:05 AM EDT - 4 months ago

Rigel to Participate in Upcoming September Investor Conferences

Overlooked Stock: RIGL Nearly Doubles Stock in August

Aug 15, 2025, 5:20 PM EDT - 4 months ago

Overlooked Stock: RIGL Nearly Doubles Stock in August

The Big 3: OPEN, RIGL, JOBY

Aug 15, 2025, 12:00 PM EDT - 4 months ago

The Big 3: OPEN, RIGL, JOBY

JOBY OPEN

Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout

Aug 13, 2025, 11:58 PM EDT - 4 months ago

Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:02 PM EDT - 5 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 4:01 PM EDT - 5 months ago

Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

Jul 29, 2025, 8:05 AM EDT - 5 months ago

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

Rigel to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:05 AM EDT - 7 months ago

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

May 22, 2025, 5:20 PM EDT - 7 months ago

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

May 7, 2025, 6:16 PM EDT - 8 months ago

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:13 PM EDT - 8 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 4:01 PM EDT - 8 months ago

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Apr 29, 2025, 8:05 AM EDT - 8 months ago

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

Apr 4, 2025, 3:31 PM EDT - 9 months ago

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Mar 27, 2025, 8:05 AM EDT - 9 months ago

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Rigel Appoints Mark W. Frohlich, M.D.

Mar 10, 2025, 8:05 AM EDT - 10 months ago

Rigel Appoints Mark W. Frohlich, M.D.

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 11:29 PM EST - 10 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 4:01 PM EST - 10 months ago

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 25, 2025, 8:05 AM EST - 10 months ago

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Jan 22, 2025, 8:05 AM EST - 1 year ago

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Rigel Provides Business Update and 2025 Outlook

Jan 13, 2025, 8:05 AM EST - 1 year ago

Rigel Provides Business Update and 2025 Outlook

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Jan 9, 2025, 8:05 AM EST - 1 year ago

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 8:05 AM EST - 1 year ago

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Dec 30, 2024, 8:30 AM EST - 1 year ago

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Dec 9, 2024, 12:02 PM EST - 1 year ago

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Dec 2, 2024, 8:05 AM EST - 1 year ago

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 8:05 AM EST - 1 year ago

Rigel to Present at the Jefferies London Healthcare Conference

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:25 PM EST - 1 year ago

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:01 PM EST - 1 year ago

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 9:05 AM EST - 1 year ago

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Oct 31, 2024, 8:05 AM EDT - 1 year ago

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Oct 24, 2024, 4:35 PM EDT - 1 year ago

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Oct 16, 2024, 10:00 AM EDT - 1 year ago

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Rigel Pharmaceuticals: Looking For More Growth

Oct 10, 2024, 7:32 AM EDT - 1 year ago

Rigel Pharmaceuticals: Looking For More Growth

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 9, 2024, 8:42 PM EDT - 1 year ago

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Oct 4, 2024, 8:05 AM EDT - 1 year ago

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel to Present at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 8:05 AM EDT - 1 year ago

Rigel to Present at the 2024 Cantor Global Healthcare Conference

SmartOptionsAlert
SmartOptionsAlert Dec. 25 at 10:43 PM
🔎 $RIGL Options Scan Update (16:43 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 25 at 4:57 PM
Enter: $RIGL Calls Strike Price: $45 Expiry Date: JAN 16 2026 Buy in Price: $2.00 - $4.60 Sell Price: $3.04 Profit : +52% (Turn every $1 into $1.52) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
1iquid
1iquid Dec. 25 at 10:09 AM
💎 Liquid® Live Actionable Trade Asset: $RIGL Contracts: $RIGL June 18, 2026 $45 Calls Scale in: $7.07- $8.64 Scale out: $27.49-$47.13 Profit Potential : 211% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
B4I4QQTRU18
B4I4QQTRU18 Dec. 25 at 12:27 AM
$RIGL 2,824,418 shares short. Not as much as I thought based on the two heavy down days. But still a lot to cover. ~16%. Board please announce a buy back plan or a drug addition. Sitting on cash is not a good look.
1 · Reply
Berakhot
Berakhot Dec. 24 at 3:38 PM
$RIGL indeed... business channel's off... trading done, fireplace stoked, rush is over, a few gifts to wrap. Christmas eve is here and delicious food ready for tomorrow. Wish you and yours a Merry Christmas Rigelians and a Happy New Years to come. https://www.youtube.com/watch?v=jBjt5gFbNYI
0 · Reply
GO_DAWGS
GO_DAWGS Dec. 24 at 1:14 PM
$RIGL Merry Christmas all!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 7:05 AM
Enter: $RIGL Calls Strike Price: $45 Expiry Date: JAN 16 2026 Buy in Price: $1.60 - $1.68 Sell Price: $3.52 Profit : +120% (Turn every $1 into $2.20) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
B4I4QQTRU18
B4I4QQTRU18 Dec. 23 at 8:31 PM
$RIGL Tomorrow new short interest report. About Two weeks, business update. IMO, blow out 4Q. Enjoy your holidays.
0 · Reply
MaxKlim
MaxKlim Dec. 23 at 3:57 PM
$RIGL https://www.marketbeat.com/instant-alerts/rigel-pharmaceuticals-nasdaqrigl-upgraded-to-buy-at-wall-street-zen-2025-12-21/
0 · Reply
GO_DAWGS
GO_DAWGS Dec. 23 at 2:59 PM
$RIGL be ready when they try to drag it down … dry powder!!!
0 · Reply
Namhguab
Namhguab Dec. 23 at 2:33 PM
$RIGL look how low this volume is now wow
0 · Reply
Berakhot
Berakhot Dec. 23 at 2:16 PM
$RIGL Thosszzz Dang illuminatians... ;-) up to their same old tricks every quarter!
0 · Reply
MaxKlim
MaxKlim Dec. 23 at 1:58 PM
$RIGL
0 · Reply
Namhguab
Namhguab Dec. 23 at 1:55 PM
$RIGL try more like 10 months now..
0 · Reply
QuarterlyTrader
QuarterlyTrader Dec. 23 at 12:50 PM
$RIGL just like the last two quarters. This bad boy gets pulled down by the Illuminati. That’s when you back up the truck for 30-45 days - buy and wait. In the 401k so you can play it with no tax man. We will be at $50+ after earnings get announced. It will pop and I will sell. And smile. Holding my long term position but swi going the quarterly position rinse. Repeat. Come join the party. Do t believe me? Look at the history. It repeats. $$$$$$$$$$&&&$$$$$$
0 · Reply
MaxKlim
MaxKlim Dec. 22 at 4:06 PM
$RIGL https://clinicaltrials.gov/study/NCT07130695
0 · Reply
MaxKlim
MaxKlim Dec. 22 at 3:23 PM
$RIGL
0 · Reply
Namhguab
Namhguab Dec. 22 at 3:00 PM
$RIGL very light volume and going up. I think all this is just covering. No one is selling and the institutional ownership has been rising the last few months. Not sure how far from this end game we are but I was hoping it was going to be this week.
0 · Reply
mitgodog
mitgodog Dec. 22 at 2:40 PM
$RIGL Same game as last Friday???
1 · Reply
Springsman72
Springsman72 Dec. 22 at 2:40 PM
$RIGL
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 22 at 1:11 PM
Enter: $RIGL Calls Strike Price: $42 Expiry Date: JAN 16 2026 Buy in Price: $3.78 - $4.90 Sell Price: $5.75 Profit : +52% (Turn every $1 into $1.52) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
1iquid
1iquid Dec. 21 at 10:38 AM
💎 Liquid® Live Actionable Trade Asset: $RIGL Contracts: $RIGL June 18, 2026 $43 Calls Scale in: $7.45- $9.10 Scale out: $28.96-$49.65 Profit Potential : 236% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply